CAR-T细胞治疗后细胞动力学与复发/难治性骨髓瘤的缓解和毒性相关
该研究对27例接受Idecabtagene vicleucel(Ide-cel)治疗的复发/难治性多发性骨髓瘤(RRMM)患者进行流式细胞术分析,评估BCMA靶向CAR-T细胞的扩增能力、持久性及对旁观细胞的影响。结果显示CD8+ CAR-T细胞的体内扩增与缓解相关,但持久性并非持久缓解所必需;白细胞分离日CD8+ T细胞比例增高联合成功淋巴细胞清除可积极影响结局,且高级别细胞因子释放综合征(CRS)风险可在淋巴细胞清除前识别。
要点
- CD8+ CAR-T细胞体内扩增与RRMM患者缓解相关,但持久性并非持久缓解所必需。
- 白细胞分离日CD8+ T细胞比例增高联合成功淋巴细胞清除可积极影响结局。
- 高级别CRS风险患者可在淋巴细胞清除前被识别。
核心结论
- CD8+ CAR-T细胞体内扩增与缓解相关,但持久性并非RRMM持久缓解所必需。
- 白细胞分离日CD8+ T细胞比例增高联合成功淋巴细胞清除可积极影响结局。
- 高级别CRS风险患者可在淋巴细胞清除前被识别。
研究设计与样本
- 对27例接受Ide-cel治疗的RRMM患者进行综合流式细胞术分析,评估BCMA靶向CAR-T细胞的扩增能力、持久性及对旁观细胞的影响。
主要发现
- CD8+ CAR-T细胞的体内扩增与缓解相关,但持久性并非持久缓解所必需。
- 白细胞分离日CD8+ T细胞比例增高联合成功淋巴细胞清除可积极影响结局。
- 高级别CRS风险患者可在淋巴细胞清除前被识别。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T cells revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM). However, data on cellular (CAR) T cell dynamics and the association with response, resistance or the occurrence of cytokine release syndrome (CRS) are limited. Therefore, we performed a comprehensive flow cytometry analysis of 27 RRMM patients treated with Idecabtagene vicleucel (Ide-cel) to assess the expansion capacity, persistence and effects on bystander cells of BCMA-targeting CAR T cells. Additionally, we addressed side effects, like cytokine release syndrome (CRS) and cytopenia. Our results show that in vivo expansion of CD8+ CAR T cells is correlated to response, however persistence is not essential for durable remission in RRMM patients. In addition, our data provide evidence, that an increased fraction of CD8+ T cells at day of leukapheresis in combination with successful lymphodepletion positively influence the outcome. We show that patients at risk for higher-grade CRS can be identified already prior to lymphodepletion. Our extensive characterization contributes to a better understanding of the dynamics and effects of BCMA-targeting CAR T cells, in order to predict the response of individual patients as well as side effects, which can be counteracted at an early stage or even prevented.
引用
- Fischer L, Grieb N, Born P, et al. Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma. Leukemia. 2024. PMID: 38184754. doi:10.1038/s41375-023-02129-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。